Kiniksa insider exercises 98,660 options and sells shares under 10b5-1 plan
Rhea-AI Filing Summary
Tessari Eben, Chief Operating Officer and director of Kiniksa Pharmaceuticals International, plc (KNSA), reported exercises of vested share options and subsequent sales on September 4 and 5, 2025 under a 10b5-1 plan. The reporting person exercised a total of 98,660 share options at exercise prices of $15.50 and $15.52, resulting in the acquisition of 98,660 Class A Ordinary Shares. That same week the reporting person sold 98,660 Class A Ordinary Shares in multiple brokered trades at weighted-average prices of about $35.52 and $35.66. After these transactions the reporting person beneficially owned 44,452 Class A Ordinary Shares. The 10b5-1 plan was executed on April 29, 2024, and the Form 4 was signed by an attorney-in-fact on September 8, 2025.
Positive
- Transactions executed under a 10b5-1 plan, providing a pre-established trading framework and affirmative defense
- Realized monetization of options exercised at ~$15.5 and sold at weighted-average prices around ~$35.5–$35.7, producing a material per-share gain
- Options were fully vested and exercisable at time of exercise, reducing questions about timing or special vesting treatment
Negative
- Large sale volume of 98,660 shares reduced the reporting person's beneficial ownership to 44,452 Class A Ordinary Shares, lowering insider stake
- Significant insider selling could be perceived by some investors as decreased near-term insider exposure, though executed under a plan
Insights
TL;DR: Insider exercised options and sold the resulting shares under a pre-established 10b5-1 plan, monetizing a substantial gain with limited ongoing ownership.
The reporting person exercised 98,660 options at strikes of $15.50 and $15.52 then sold the same number of shares at weighted-average prices near $35.5–$35.7, indicating a material realized gain per share. Transactions were executed under a 10b5-1 plan (April 29, 2024), which limits opportunistic timing concerns. Remaining beneficial ownership is 44,452 Class A shares, representing continued, though reduced, insider alignment. For investors, this is a routine option monetization rather than an operational signal.
TL;DR: Trades followed a documented 10b5-1 plan and involved fully vested options, so governance controls were observed.
The Form 4 discloses that the exercised options were fully vested and the sales were effected pursuant to a 10b5-1 trading plan executed April 29, 2024, which provides affirmative defense under Rule 10b5-1(c). The filing includes weighted-average sale prices and an offer to provide trade-level detail to SEC staff, reflecting transparent disclosure practices. The signature by an attorney-in-fact is typical for timely filings. Overall, governance procedures appear to have been followed.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Share Option | 13,389 | $0.00 | -- |
| Exercise | Class A Ordinary Share | 13,389 | $15.52 | $208K |
| Sale | Class A Ordinary Share | 13,389 | $35.66 | $477K |
| Exercise | Share Option | 38,725 | $0.00 | -- |
| Exercise | Share Option | 46,546 | $0.00 | -- |
| Exercise | Class A Ordinary Share | 38,725 | $15.50 | $600K |
| Exercise | Class A Ordinary Share | 46,546 | $15.52 | $722K |
| Sale | Class A Ordinary Share | 85,271 | $35.52 | $3.03M |
Footnotes (1)
- This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 29, 2024. This transaction was executed in multiple trades through a broker-dealer at prices ranging between $35.50 and $35.545. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. This transaction was executed in multiple trades through a broker-dealer at prices ranging between $35.52 and $35.84. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. The option is fully vested and exercisable.
